Hopewell Therapeutics Announces $25 Million Seed Financing to Advance Next Generation Lipid Nanoparticles for Targeted Delivery of Genomic Medicines
Company has built leading edge tissue-targeted Lipid Nanoparticle (ttLNP) technology to enable a new generation of highly targeted genomic medicines Participating venture investors include Mass Ave Capital, 5Y Capital, and HIKE Capital Advancing groundbreaking scientific research program for systemic delivery of mRNA to multiple targeted tissues in pre-clinical models, including first-ever data demonstrating highly efficient … Read more